Glenmark launches Favipiravir for treatment of mild to moderate COVID19 patients.
FabiFlu is the first oral Favipiravir-approved medication in India for the treatment of COVID-19.
Anti-viral drug Favipiravir approved for treatment of mild to moderate COVID-19 patients will be commercialised full scale in a week, says drug maker Glenmark Pharmaceuticals.
Approved by the Drug Controller General of India (DCGI) for restricted emergency use, Favipiravir marketed by Indian pharma major Glenmark as FabiFlu will be available at retail chemists and hospitals from next week onwards.
The drug is priced at ₹3,500 for a pack of 34 tablets (it is ₹103 per tablet). “It will be available in retail chemist stores and hospitals by next week, and patients will be able to access the drug with doctors’ prescription,” said Sujesh Vasudevan, President (India Formulations), Glenmark.